EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Alphamab Oncology's enterprise value is HK$3,330.7 Mil.
Alphamab Oncology's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$239.3 Mil. Therefore, Alphamab Oncology's EV-to-Revenue for today is 13.92.
The historical rank and industry rank for Alphamab Oncology's EV-to-Revenue or its related term are showing as below:
HKSE:09966'
s EV-to-Revenue Range Over the Past 10 Years
Min: 10.99 Med: 33.02 Max: 78.82
Current: 13.92
During the past 7 years, the highest EV-to-Revenue of Alphamab Oncology was 78.82. The lowest was 10.99. And the median was 33.02.
HKSE:09966's EV-to-Revenue is ranked worse than 61.2% of 1036
companies
in the Biotechnology industry
Industry Median: 8.17
vs HKSE:09966: 13.92
As of today (2024-05-29), Alphamab Oncology's stock price is HK$2.63.
Alphamab Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.25. Therefore, Alphamab Oncology's PS Ratio for today is 10.52.
Alphamab Oncology EV-to-Revenue Historical Data
The historical data trend for Alphamab Oncology's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Alphamab Oncology's EV-to-Revenue
For the Biotechnology subindustry, Alphamab Oncology's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alphamab Oncology's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alphamab Oncology's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Alphamab Oncology's EV-to-Revenue falls into.
Alphamab Oncology's current Enterprise Value is HK$3,330.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Alphamab Oncology's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$239.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alphamab Oncology's share price for today is HK$2.63.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.25.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alphamab Oncology EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Alphamab Oncology's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Alphamab Oncology (HKSE:09966) Business Description
Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in discovery, development manufacturing and commercialization of biotherapeutics for cancer treatment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09966 has been successfully added to your 